Lydia Carrera Marcolin

Ms. Lydia Carrera Marcolin

Universitat de Barcelona, Barcelona, Catalonia, Spain
orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2024 in Applied Microbiology
Verified
Journal Article
Open access
PDF file
LMLydia Carrera Marcolin
Lydia Carrera Marcolin
JCJordi Cuñé Castellana
Jordi Cuñé Castellana
LMLaia Martí Melero
Laia Martí Melero
CLcarlos de lecea
carlos de lecea
MTMaria Tintoré
Maria Tintoré
Diarrhoea is a serious cause of mortality worldwide that can lead to dehydration, gut barrier function impairment, nutrient malabsorption, and alterations of the gut microbiota (dysbiosis). The current solutions for its management, such as oral rehydration salts (ORS), inhibitors of gut motility, antibiotics, and living probiotics, only partially counteract the mechanisms of the disease and do not provide a full coverage of the problem. The potential risks of the use of living probiotic strains, particularly in immunocompromised patients, can be eliminated with the use of tyndallized (heat-killed) postbiotic bacteria and yeast. ABB C22® is a postbiotic combination of three tyndallized yeasts, namely Saccharomyces boulardii, Saccharomyces cerevisiae, and Kluyveromyces marxianus. To assess the action of the postbiotic combination on diarrhoea, immune and gut epithelial cell signalling assays, the gut barrier formation assay, and the rotavirus gene expression assay were performed. ABB C22® showed a strong anti-inflammatory effect, an induction of the build-up of the gut epithelium, and a degree of protection against rotavirus infection. These experimental studies support the use of the postbiotic ABB C22® as a solution for the management of diarrhoea and gastrointestinal conditions, alone or in combination with existing but incomplete treatments.

24 January 2025 in Genes
Verified
Journal Article
Open access
PDF file
EMEmma Fortes Marin
Emma Fortes Marin
LMLydia Carrera Marcolin
Lydia Carrera Marcolin
LMLaia Martí Melero
Laia Martí Melero
MTMaria Tintoré
Maria Tintoré
MPMireia Beltran Porres
Mireia Beltran Porres
Background/Objectives: The prevalence of the diamine oxidase (DAO) enzyme deficiency of a genetic origin has not been previously assessed. A prospective population-based study was conducted in a sample of 200 healthy newborns aimed to determine the prevalence of DAO enzyme deficiency caused by single nucleotide polymorphism (SNP) variants of the AOC1 gene. Methods: Genotyping was performed in oral mucosa samples collected around 2 days after birth. The four more frequent SNPs, c.47C>T (rs10156191), c.995C>T (rs1049742), c.1990C>G (rs10449793), and c.691G>T (rs2052129), were analyzed. Results: DAO deficiency was present in 132 newborns, with a prevalence of 66% (95% confidence interval [CI] 59–73%). The rs10449793 variant showed a prevalence of 46%, followed by rs10156191 with a prevalence of 42.5%, and rs2052129 with a prevalence of 39.5%. The variant rs1049742 showed the lowest prevalence (9.5%). The frequency of one, two, three, or four SNPs was 23%, 23.5%, 10.5%, and 9%, respectively. In all fours SNP variants, heterozygous carriers were more frequent than homozygous carriers (19% homozygosity). Differences in the prevalence of DAO deficiency between males (68%, 66/96) and females (63.4%, 66/104) were not found (p = 0.885). The prevalence in Caucasian newborns was 66.5% (123/185), as compared with 60% (9/15) in Latin Americans (p = 0.821). Conclusions: This study carried out in healthy newborns indicates that there is a high prevalence (66%) of DAO deficiency of a genetic origin in the general population.

Verified
Journal Article
Open access
PDF file
PPPol Molina Perelló
Pol Molina Perelló
MRMontse Puntes Rodríguez
Montse Puntes Rodríguez
JHJimena Coimbra Hurtado
Jimena Coimbra Hurtado
MSMaite Garrido Sánchez
Maite Garrido Sánchez
MOMarta Castillo Ocaña
Marta Castillo Ocaña
RARosa Antonijoan Arbós
Rosa Antonijoan Arbós
Background/Objectives: Diamine oxidase (DAO) enzyme metabolizes dietary histamine in the gastrointestinal tract. DAO deficiency can lead to histamine intolerance (HIT), manifesting as migraines, gastrointestinal disturbances, and allergic reactions. DAO supplementation has been shown to enhance histamine breakdown, alleviating these symptoms. This randomized, double-blind, single ascending dose (SAD) Phase I clinical trial aimed to evaluate the safety and tolerability of escalating doses of DAO supplementation in healthy volunteers. Methods: Thirty participants were randomly assigned to receive single doses of 42 mg, 84 mg, or 210 mg of DAO extract (adiDAO® Veg) or placebo under fasting conditions. Vital signs, laboratory parameters, and adverse events (AEs) were monitored. Results: No serious adverse events or clinically significant changes in vital signs, ECGs, or laboratory parameters were observed. Conclusions: This trial confirms the safety and tolerability of high-dose DAO supplementation. Future studies are recommended to explore the effects of chronic high-dose administration and alternative dosage forms to improve convenience.

6 December 2024 in medRxiv
Verified
Preprint
Open access
PDF file
PPP. Molina Perelló
P. Molina Perelló
MRM. Puntes Rodríguez
M. Puntes Rodríguez
JHJ. Coimbra Hurtado
J. Coimbra Hurtado
MSM. Garrido Sánchez
M. Garrido Sánchez
MOM. Castillo Ocaña
M. Castillo Ocaña
RAR. Antonijoan Arbós
R. Antonijoan Arbós
Diamine oxidase (DAO) is a key enzyme for metabolizing dietary histamine in the gastrointestinal tract. DAO deficiency can lead to histamine intolerance (HIT), manifesting as migraines, gastrointestinal disturbances, and allergic reactions. DAO supplementation has been shown to enhance histamine breakdown, alleviating these symptoms. This randomized, double-blind, single ascending dose (SAD) Phase I clinical trial aimed to evaluate the safety and tolerability of escalating doses of DAO supplementation in healthy volunteers. Thirty participants were enrolled and randomly assigned to receive DAO or placebo. Single doses of 42 mg, 84 mg, or 210 mg of DAO extract (adiDAO® Veg) were administered under fasting conditions. Vital signs, laboratory parameters, and adverse events (AEs) were monitored, and a follow-up visit assessed post-administration safety. All participants completed the study without discontinuations. No serious adverse events or clinically significant changes in vital signs, ECGs, or laboratory parameters were observed. The study demonstrated that even doses significantly exceeding typical recommendations were well-tolerated, with no safety concerns identified. This trial confirms the safety of high-dose DAO supplementation, supporting its potential use in managing DAO deficiency and HIT. Future studies are recommended to explore the effects of chronic high-dose administration and alternative dosage forms to improve convenience.

8 April 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
LMLydia Carrera Marcolin
Lydia Carrera Marcolin
JCJordi Cuñé Castellana
Jordi Cuñé Castellana
LMLaia Martí Melero
Laia Martí Melero
CLcarlos de lecea
carlos de lecea
MTMaria Tintoré
Maria Tintoré
Diarrhoea is a serious cause of mortality worldwide that can lead to dehydration, gut barrier function impairment, nutrient malabsorption, and alterations of the gut microbiota (dysbiosis). Current solutions for its management, such as oral rehydration salts (ORS), inhibitors of the gut motility, antibiotics, and living probiotics only partially counteract the mechanisms of the disease and do not provide a full coverage of the problem. Potential risks of the use of living probiotic strains, particularly in immunocompromised patients, can be eliminated with the use of tyndallized (heat-killed) postbiotic bacteria and yeast. ABB C22® is a postbiotic combination of three tyndallized yeasts, namely Saccharomyces boulardii, Saccharomyces cerevisiae, and Kluyveromyces marxianus. To assess the action of the postbiotic combination on diarrhoea, immune and gut epithelial cell signaling assays, gut barrier formation assay and rotavirus gene expression assay were performed. ABB C22® showed a strong anti-inflammatory effect, an induction of the build-up of the gut epithelium, and a degree of protection against rotavirus infection. These experimental studies support the use of the postbiotic ABB C22® as a solution for the management of diarrhoea and gastrointestinal conditions, alone or in combination with existing but incomplete treatments.

10 April 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
LMLydia Carrera Marcolin
Lydia Carrera Marcolin
JCJordi Cuñé Castellana
Jordi Cuñé Castellana
LMLaia Martí Melero
Laia Martí Melero
CLcarlos de lecea
carlos de lecea
MTMaria Tintoré
Maria Tintoré
Diarrhoea is a serious cause of mortality worldwide that can lead to dehydration, gut barrier function impairment, nutrient malabsorption, and alterations of the gut microbiota (dysbiosis). Current solutions for its management, such as oral rehydration salts (ORS), inhibitors of the gut motility, antibiotics, and living probiotics only partially counteract the mechanisms of the disease and do not provide a full coverage of the problem. Potential risks of the use of living probiotic strains, particularly in immunocompromised patients, can be eliminated with the use of tyndallized (heat-killed) postbiotic bacteria and yeast. ABB C22® is a postbiotic combination of three tyndallized yeasts, namely Saccharomyces boulardii, Saccharomyces cerevisiae, and Kluyveromyces marxianus. To assess the action of the postbiotic combination on diarrhoea, immune and gut epithelial cell signaling assays, gut barrier formation assay and rotavirus gene expression assay were performed. ABB C22® showed a strong anti-inflammatory effect, an induction of the build-up of the gut epithelium, and a degree of protection against rotavirus infection. These experimental studies support the use of the postbiotic ABB C22® as a solution for the management of diarrhoea and gastrointestinal conditions, alone or in combination with existing but incomplete treatments.